South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and development unit, have secured a bid to supply its biosimilar Hadlima (adalimumab-bwwd), a treatment for autoimmune diseases, to the US Department of Veterans Affairs (VA).
Hadlima is a biosimilar of Humira, developed by the multinational pharmaceutical company AbbVie Inc. It addresses conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
Under the contract, Samsung Bioepis and Organon will supply Hadlima to VA hospitals for the next five years.
It becomes the exclusive supplier among medications containing this active ingredient, including the original drug. The specific contract amount remains undisclosed.
Write to Dae-Kyu Ahn at powerzanic@hankyung.com
Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official designation from the US Food and Drug Administration (FDA) as interchangeable with the original medicine. Samsung Bioepis is thus South Korea’s fi
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli, which references Alexion Pharmaceuticals Inc.’s rare blood disease medicine, Soliris. According to the pharmaceutical and biotech industry
Samsung Bioepis headquarters Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partnership agreement with Swiss pharmaceutical company Sandoz for sales of autoimmune disease treatment Stelara (act
Researcher at Samsung Bioepis' laboratory (Courtesy of Samsung) Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business division of Nasdaq-listed Biogen Inc. at less than 1 trillion won ($775.3 million),
South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-selling treatment for autoimmune diseases such as rheumatoid arthritis, has received a major boost in this venture.Prime Therapeutics, the No. 5 P